The short version
- A 2023 Cochrane review of 17 randomised trials of blue-light filtering lenses performed no meta-analysis for any outcome, citing a lack of quantitative data and heterogeneous populations and follow-up periods.
- That review rated the evidence on sleep quality as very low certainty, with three of six relevant trials reporting improvement and three reporting no significant difference.
- A meta-analysis restricted to double-blind crossover trials with actigraphy found only three eligible studies totalling 49 people, and no significant effect on sleep onset latency, total sleep time, sleep efficiency or wake after sleep onset.
- The two most-cited positive trials enrolled 14 and 20 participants respectively, and their significant findings were almost entirely self-reported.
- Cochrane found blue-light filtering lenses may not reduce eye strain from computer use, which is the claim most of these lenses are marketed on.
Amber glasses are the rare sleep intervention with no supplement industry behind it, which ought to make the evidence cleaner. It does not. The largest review of the field could not combine its own studies, and the trials that do exist are small enough that both believers and sceptics can quote them accurately.
What Cochrane found, and did not
Singh and colleagues reviewed blue-light filtering spectacle lenses for the Cochrane Database in 2023: 17 randomised controlled trials, with sample sizes ranging from five to 156 participants, and follow-up periods from less than a day to five weeks.
They performed no meta-analysis for any outcome. Not because the results were negative, but because of a lack of available quantitative data, heterogeneous populations, and differing follow-up periods. None of the 17 studies had a low risk of bias across all seven domains; 65% were judged at high risk of detection bias because outcome assessors were not masked.
On sleep specifically, their verdict was: we do not know whether blue-light filtering lenses are equivalent or superior to non-filtering lenses with respect to sleep quality — very low-certainty evidence. Six trials in 148 participants reported inconsistent findings; three found significant improvement, three found no significant difference. On eye strain, the review found blue-light filtering lenses may not attenuate symptoms of eye strain with computer use, which is the claim most of these lenses are actually marketed on.
Adverse events were infrequent but not zero, and the list is worth seeing: increased depressive symptoms, headache, discomfort wearing the glasses, and lower mood.
The meta-analysis that did happen, on actigraphy
Luna-Rangel and colleagues published a narrower meta-analysis in Frontiers in Neurology, restricted to double-blind crossover randomised trials with actigraphy-derived outcomes. That restriction left them three trials totalling 49 participants.
Sleep onset latency: a non-significant reduction of 4.86 minutes (95% CI −20.23 to 10.52). Total sleep time: a non-significant increase of 8.75 minutes (95% CI −35.31 to 52.82). No significant effect on sleep efficiency or wake after sleep onset. Heterogeneity was zero, which means the studies agreed with each other — they agreed on finding nothing certain. Their conclusion: blue-light blocking glasses may provide small improvements, but current randomised evidence does not support significant effects.
The two trials people quote, in full
They are quoted because they are positive, and they are worth reading rather than dismissing.
Shechter and colleagues ran a randomised crossover in 14 people with insomnia symptoms, wearing amber lenses or clear placebo lenses for two hours before bed for seven nights, with a four-week washout. Pittsburgh Insomnia Rating Scale total scores improved with amber lenses, as did subjective total sleep time, overall quality and soundness of sleep. Of the actigraphic measures, only total sleep time reached significance. Fourteen people.
Burkhart and Phelps randomised 20 volunteers to amber or yellow-tinted control glasses for three hours before sleep, with sleep diaries over one baseline week and two intervention weeks. The amber group's sleep quality improved significantly relative to control, as did positive affect. Outcomes were entirely subjective, and — a detail that matters — sleep quality at study outset was poorer in the amber group, which is the setup where regression toward the mean flatters the intervention.
Fourteen people and twenty people, both mostly self-reported. That is the strong case.
What we think is actually going on
The mechanism is not in doubt. Evening blue light suppresses melatonin and delays circadian phase; that is established physiology. What is in doubt is whether wearing tinted lenses for two hours in the evening removes enough of it to change your night, particularly when you are still holding the bright screen that the light comes from.
Our reading: the glasses may be a proxy for the behaviour. Putting on amber glasses at 9pm is a ritual that announces the evening is ending, and rituals do things. That is not nothing, and it is also not what the £40 is being sold for.
There is one group with a stronger case, and it is not the general public. If you work night shifts, controlling light exposure is a genuine circadian lever rather than a lifestyle tweak — though even there, the Cochrane review of shift-work interventions rated the bright light evidence very low quality.
What we'd actually tell you
If you already own a pair and feel they help, keep wearing them. The harm is negligible, the cost is sunk, and self-reported sleep quality is a real thing to improve even if an actigraph disagrees.
If you are deciding whether to buy: this is not where your next £40 should go. The interventions with sturdier numbers behind them are free — caffeine at least six hours before bed, moving your last drink earlier, keeping a fixed wake time. Standard sleep hygiene is a weak treatment, and it still has better evidence than this does.
And notice which claim you are buying. Most of these lenses are marketed for digital eye strain, and that is the claim Cochrane came closest to actually rejecting.
Good questions
Do blue-light blocking glasses actually improve sleep?
The honest answer is that nobody can say yet. A 2023 Cochrane review of 17 trials rated the sleep evidence very low certainty and could not pool a single outcome, with three trials showing improvement and three showing none. A narrower meta-analysis of actigraphy data in 49 people found no significant effect on any objective sleep measure.
Are blue-light glasses worth the money?
Not as your next purchase. If you already own a pair and feel they help, the harm is negligible and self-reported sleep quality matters. But if you are choosing where to spend, caffeine timing, moving your last drink earlier and a fixed wake time all have better evidence behind them and cost nothing at all.
Do blue-light glasses help with eye strain from screens?
That is the claim the evidence comes closest to rejecting. The Cochrane review concluded that blue-light filtering lenses may not attenuate symptoms of eye strain with computer use over short-term follow-up, and found probably little or no effect on visual acuity. It is also the claim most of these lenses are actually sold on.
Can blue-light glasses have side effects?
Rarely, but the reported list is not empty. Across nine trials that reported on adverse events, the effects associated with blue-light filtering lenses included increased depressive symptoms, headache, discomfort wearing the glasses, and lower mood. These were infrequent and the evidence was low certainty. It is still more than the marketing implies.
Is it better to just put the phone down?
Probably, and it is free. Evening blue light suppressing melatonin is established physiology; what is unproven is whether tinted lenses remove enough of it while you are still holding the bright screen. Part of what these glasses may be doing is acting as a ritual that ends the evening, and you can run that ritual without buying anything.
Sources
- Singh S, Keller PR, Busija L, et al. Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults. Cochrane Database Syst Rev, 2023. View study
- Luna-Rangel FA, Gonzalez-Bedolla B, Salazar-Ortega MJ, Torres-Mancilla XM, Martinez-Cadena S. Efficacy of blue-light blocking glasses on actigraphic sleep outcomes: a systematic review and meta-analysis of randomized controlled crossover trials. Front Neurol, 2025. View study
- Shechter A, Kim EW, St-Onge MP, Westwood AJ. Blocking nocturnal blue light for insomnia: A randomized controlled trial. J Psychiatr Res, 2018. View study
- Burkhart K, Phelps JR. Amber lenses to block blue light and improve sleep: a randomized trial. Chronobiol Int, 2009. View study
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
